2025 Interim Financial Highlights and 2025 Outlook of IGG Inc:The Group’s revenue for the first half reached HK$2.72 billion, remaining stable compared to the same period last year. “Doomsday: Last Survivors” and “Viking Rise” contributed approximately HK$520 million and HK$360 million respectively, while the APP Business[1] generated HK$530 million in revenue for the Group. “Lords Mobile”, IGG’s flagship title launched nine years ago, contributed HK$1.15 billion.“Fate War”, released in early August, has achieved gross billing of HK$20 million[2] in three weeks, attributed to its high quality and innovative gameplay, providing a new growth driver for the Group.The Group achieved a net profit of HK$320 million in the first half of 2025, an increase of 29% compared to the second half of 2024. The Group’s net profit for core business (non-IFRS measure)[3] reached HK$340 million, while the investment business recorded an unrealized loss of approximately HK$20 million due to fair-value changes of investees.The Board of Directors declared an interim dividend of HK8.3 cents per ordinary share, and a special dividend of HK5.6 cents per ordinary share. Total dividends declared for the period amounted to HK13.9 cents per ordinary share, representing approximately 50% of interim profit. The Group allocated approximately HK$35 million for share buy-backs, which corresponds to approximately 11% of interim profit. The total dividends declared, plus share buy-backs, accounted for 61% of interim profit.HONG KONG, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - IGG Inc (“IGG” or the “Group”, stock code: 799.HK), a leading global developer and publisher of mobile games and applications, announces its unaudited consolidated interim results for the six months ended 30 June 2025.Amid rising competition in the gaming market, the Group remains undaunted by these challenges and continues to advance its diversified development initiatives. In the first half of 2025, the Group achieved revenue of HK$2.72 billion, remaining stable compared to the same period last year. “Doomsday: Last Survivors” and “Viking Rise” contributed approximately HK$520 million and HK$360 million respectively, while the APP Business generated HK$530 million in revenue for the Group. These three contributors accounted for 52% of the Group’s revenue. “Lords Mobile”, IGG’s flagship title launched nine years ago, contributed approximately HK$1.15 billion. During the period, revenue from Asia, Europe and North America accounted for 42%, 35% and 19%, respectively, of the Group’s total revenue.In the first half of 2025, the Group reported a net profit of HK$320 million, which remained relatively flat compared to the same period last year, but marked an increase of 29% compared to the second half of 2024. During the period, the Group increased its marketing expense by 10% year-on-year, aimed at expanding user acquisition and extending product life spans. The Group’s net profit for core business (non-IFRS measure) achieved HK$340 million, while the investment business recorded an unrealized loss of approximately HK$20 million due to fair-value changes of investees. As at 30 June 2025, the Group’s mobile games were available in 23 different languages worldwide, with approximately 1.6 billion gamers in total and over 15 million monthly active users (“MAU”) across more than 200 countries and regions.Since its launch, the game “Doomsday: Last Survivors” has regularly introduced new features, including new team formation “Off-Limits War”, which significantly enhanced gamer engagement. Additionally, the game ran a series of collaborations with different partners, including hit movies “Pacific Rim” and “Godzilla x Kong: The New Empire”, all of which were well-received by its 86 million players[4]. The Group is gearing up once again for the “2025 World Championship” featuring “Lords Mobile”, “Doomsday: Last Survivors”, and “Viking Rise”, allowing players to experience the thrill of live competitive gaming. In the first half of 2025, the game contributed HK$520 million in revenue, representing a 6% increase year-on-year.“Viking Rise”, the Group’s first Viking-themed strategy game, received widespread acclaim when it was launched in late 2022. Throughout the period, the game continued to introduce new features, including a new jewel equipment system, and a new conquest season, to provide gamers a fresh experience. Additionally, the game introduced a series of IP collaborations and participated in game events globally. As at 30 June 2025, it has approximately 53 million registered users. In the first half of 2025, the game generated HK$360 million in revenue, an 18% year-on-year increase.“Lords Mobile”, IGG’s blockbuster title that debuted nine years ago, is the Group’s first cross-platform, multi-language, real-time game, lauded by Sensor Tower for its longevity[5], and designed for a global audience. It has received widespread acclaim from gamers, and consistently generates stable revenue for the Group. As at 30 June 2025, it has amassed 770 million registered users worldwide. During the period, the game introduced IP collaborations with “Terracotta Warriors of Qin Shihuang”, “Coca-Cola”, and hit movie “Pacific Rim”, alongside offline tournaments and gamers’ meetup events.Leveraging the Group’s global operational expertise and a base of more than 1 billion users, the APP Business achieved significant breakthroughs and remarkable growth over the past two years. It reached over 73 million MAU, representing an increase of 79% compared to the same period last year. In the first half of 2025, it generated HK$530 million in revenue, an increase of 30% year-on-year, and accounted for approximately 20% of the Group’s total revenue. The APP Business has emerged as a vital growth driver for the Group, contributing a noteworthy net profit of HK$73 million, representing 22% of the Group’s net profit.“Fate War”, which was released in early August, has been well received by players. Upon launch, “Fate War” was ranked among the top three[6] on the iOS simulation games download list in 22 countries and regions, including the U.S., Japan, Korea, Germany, France, England, Italy, and others. It not only earned acclaim from gamers for its free movement and play mode, but was also prominently featured on Apple’s App Store and Google’s Play Store worldwide. The game uniquely blends simulation and strategy gameplay, along with rich tactical battles. As at 27 August 2025, the game has 1.2 million registered users and 1.2 million MAU, with HK$20 million in gross billing, underscoring its significant growth potential.Through a combination of share repurchases and dividend payouts, the Group consistently returns value to its shareholders. During the period, the total amount declared in dividend, together with the funds allocated for share repurchases, accounted for approximately 61% of the Group’s net profit for the first half of 2025. The Board of Directors declared an interim dividend of HK8.3 cents per ordinary share, and a special dividend of HK5.6 cents per ordinary share. Total dividends declared for the period amounted to HK13.9 cents per ordinary share, representing approximately 50% of interim profit. In the first half, the Group allocated approximately HK$35 million for share buy-backs, which corresponds to approximately 11% of interim profit.Entering the second half, the Group will continue to enhance its gaming and APP Business, with a commitment to sustaining long-term profitability. Embracing the corporate spirit of “Innovators at Work, Gamers at Heart”, the Group will continue to strengthen its global R&D and operational capabilities, to relentlessly pursue its strategy of quality, innovation, and excellence in creating innovative yet timeless games.About IGG IncEstablished in 2006, IGG Inc is a leading global mobile games and applications developer and operator with headquarters in Singapore and local offices in the United States, China, Canada, Japan, South Korea, Thailand, the Philippines, Indonesia, Brazil, Türkiye, Italy and Spain. IGG offers multi-language and multifarious games and mobile applications to users around the world. The Group has established long-term partnerships with over 100 business partners, including global platforms, advertising channels, and vendors such as Apple, Google and Meta. IGG’s most popular games include “Lords Mobile”, “Doomsday: Last Survivors”, “Viking Rise”, “Time Princess”, “Fate War”, along with a range of diversified mobile applications.[1] APP Business: development and operations of the Group’s mobile applications.[2] Gross billing as at 27 August 2025.[3] Net profit for core business (non-IFRS measure): net profit excluding gain/loss on investments. Gain/loss on investments including: (1) fair value change and gain/loss on disposal of other financial assets or liabilities and assets held for sale, and dividend income; and (2) share of results of associates and joint ventures, impairment loss on interest in associates and joint ventures and net gain/loss on disposal and deemed disposal of associates and joint ventures.[4] User data as at 30 June 2025.[5] Source: Sensor Tower, a third-party analytics platform[6] Ranking data: as at 27 August 2025 from a third-party analytics platform data.ai Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Performance Summary:Revenue increased by 30% to HK$2.825 billion, setting a new mid-year recordNet profit after tax surged by 182% to HK$550 millionROE (annualized) significantly improved to 7.3%Declared an interim dividend of HK$0.05 per share, with a payout ratio of 87%Significant increases in commission and fee income, interest income, and trading and investment income, reaching HK$541 million, HK$1.196 billion, and HK$1.088 billion, respectivelyBusiness Highlights:Full-chain coverage of digital asset business, including “Trading (Consulting) + Client Introducing + Product Issuance + Distribution”Robust growth in wealth management, with the segment's revenue accounting for 32% of the total. Brokerage income increased by 46%, and commission income from Hong Kong stock soared by 131%, outperforming the marketCorporate finance underwriting fee income increased by 85%, with the number of placement projects ranking 1st in the marketRanked 1st in the market for both the number of offshore Chinese bonds underwriting and the underwriting amount among Chinese securities firmsRanked 1st among Chinese securities firms in terms of trading volume of on-exchange Hong Kong stock derivativesContinuous expansion of the Cross-Boundary Wealth Management Connect 2.0 product pool, and the “Junhong Global” APP continuously upgraded to empower global asset allocationReceived Moody's "Baa2" and S&P's "BBB+" long-term issuer ratings for ten consecutive years, with a "stable" outlookMSCI ESG rating of A, achieving operational carbon neutrality for the third consecutive year HONG KONG, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, the “Group”, stock code: 1788.HK), a company of Guotai Haitong Group, adhered to its prudent and pragmatic business philosophy, anchoring its development direction in “Advancing from Stability Towards Innovation”. By maintaining rigorous risk controls while comprehensively enhancing its diversified business capabilities and actively driving business innovation, the Group achieved synergistic growth across all core businesses with high-quality results, with wealth management, corporate finance, investment management and other areas showing particular strength, driving an overall increase in commission and fee income, interest income, and trading and investment income. During the period, the Group’s revenue reached HK$2.825 billion, an increase of 30% YOY, hitting a record high, the profit attributable to ordinary equity holders was HK$550 million, surging by 182% YOY, achieving a leapfrog growth in profitability.The Group’s achievements have been widely recognised by the market. As at 30 June 2025, the Company’s market capitalisation reached HK$32.7 billion, surging 200% from the end of 2024, and as of the date of this news release, the market capitalization exceeded HK$50 billion，representing a significant increase in market value. To express gratitude for investors’ long-term recognition and support, the Company maintains a high dividend payout ratio to share the benefits of its development, the Board declared an interim dividend of HK$0.05 per for the six months ended 30 June 2025 (payout ratio: 87%).Wealth Management: Deepening Diversification While Accelerating InnovationIn the first half of 2025, the Group actively seized market opportunities through multiple initiatives to provide clients with diversified products and services. The integrated wealth management platform maintained the coordinated development across equities, bonds, funds, derivatives and other products, driving a significant increase of 56% YOY in commission income to HK$279 million. The Group continuously upgraded its investment and trading APP “Junhong Global” to enhance customer experience, while strengthening the provision of precise asset allocation service for high-net-worth clients. Since pioneering the launch of its Cross-boundary Wealth Management Connect 2.0 service at the end of 2024, the Group has continuously enriched its product pools to provide qualified mainland investors with a secure and convenient one-stop investment platform. At the same time, the Group increased its allocation to fixed income assets with low risk, high ratings and liquidity at appropriate times, laying a solid foundation for wealth management products and enhancing market competitiveness.Corporate Finance: Focused on Key Sectors, Top-tier Bond UnderwritingThe Group facilitated fundraising for numerous high-quality enterprises across equity and debt capital markets, driving a significant increase of 85% YOY in placing, underwriting and sub-underwriting commission income to HK$165 million. In the first half of 2025, the Group participated in the issuance and underwriting of 150 bonds, an increase of 33% YOY, with a total issuance scale of approximately HK$258.8 billion, increased by 38% YOY. According to data from the bond platform of DMI of CSCI Technology Co., Limited, the Group ranked first in the market in terms of the number of lead underwriting projects, and ranked first among Chinese securities firms in terms of total lead underwriting amount, for Chinese-issued offshore bonds.In the equity financing business, the Group continued to strengthen synergistic collaboration with its parent company, Guotai Haitong, with focused coverage on cutting-edge sectors such as new energy, robotics, and autonomous vehicles, which significantly enhanced its project penetration in market focus segments. Leveraging its professional expertise in capital operations and project execution, the Group, as the joint global coordinator and joint bookrunner, assisted Contemporary Amperex (3750.HK) in completing its Hong Kong IPO project and facilitated 18 companies to successfully submit their Main Board listing applications to the Stock Exchange (excluding confidential submissions). In the first half of the year, the Group, as the placing agent, also underwrote 12 Hong Kong secondary offering projects, ranking first in the market, serving companies such as iMotion Automotive Technology (1274.HK), XtalPi Holdings (2228.HK), UBTECH Robotics (9880.HK), Lopal Tech (2465. HK) , etc.Institutional Business: Steady Growth Anchored by Optimised Product and Service InnovationThe Group closely collaborated with its parent company, Guotai Haitong, to integrate the resources, channels, and expertise of both parties in domestic and overseas markets, thus providing comprehensive cross-border, cross-asset, and cross-market products and trading services for institutional clients, constantly enriching its product matrix and expanding the scope of trading coverage. In the Hong Kong stock derivative market, the Group achieved a significant YOY growth in trading volume in the first half of the year by continuously enhancing product design and trading capabilities and increasing marketing efforts, with the trading scale of on-exchange Hong Kong stock derivatives ranking first among the Chinese securities firms. As of 30 June, the scale of the Company’s financial product business reached HK$41.74 billion, an increase of 4% as compared to that as at the end of 2024. In the first half of 2025, the Group was among the first to participate in Bond Connect (Northbound) offshore RMB-denominated bond repo business. In April, the Group was awarded the “Exchange Traded Products Awards – Top Breakthrough Broker” by the Stock Exchange for its outstanding performance in the trading volume of ETFs in 2024, reflecting the continuously rising market recognition.Full-chain coverage of digital asset business, pioneering digital development in financial industryBuilding upon its established wealth management business, the Group has actively expanded into new business areas. After obtaining the no objection approval from the SFC to conduct business in offering, issuing and distributing of virtual-asset-related products (including OTC derivatives) and approval as a virtual asset dealing introducing agent in 2024, the Group further obtained confirmation to distribute tokenized securities to clients and provide advice on tokenized securities in May 2025. In June, it received the SFC’s approval to uplift its existing Type 1 (dealing in securities) regulated activity license, to provide virtual asset dealing services under an omnibus account arrangement with SFC-licensed platforms. In this respect, the Group has established a comprehensive service capability on digital-asset-related businesses, helping clients in unlocking new wealth-building potentials. In July, the Group successfully issued the first public digital native bond of the Chinese securities firm. In August, it achieved the successful issuance of the first batch of structured native token products, marking a major breakthrough in fintech innovation. The Group has become the first Hong Kong-based Chinese securities firm with all-round service capabilities for digital asset-related businesses, achieved full-chain coverage of digital asset "Trading (Consulting) + Client Introducing + Product Issuance + Distribution", helping clients seize new opportunities for financial growth.ESG: Concurrent Triumphs in Green Finance and Low-Carbon OperationThe Group, adhering to the belief of “Finance for the Country, Finance for the People, Finance for the Good”, has integrated and deepened ESG concepts into its daily business operations and management, striving to build a responsible comprehensive financial service platform. In terms of green finance, the Group has strengthened its ESG bond market leadership by completing 47 ESG bond issuances, raising approximately HK$102.7 billion, ranking first among Chinese securities firms in DMI’s China offshore ESG bond league tables in terms of lead underwriting amount, demonstrating its leading position in green finance. In terms of low-carbon operation, on the basis of persisting in energy conservation and emission reduction, the Group successfully offset its Scope 1 and Scope 2 GHG emissions (609.29 tonnes of CO2 equivalent) in 2024 by purchasing carbon credit assets of the VCS forestry projects, achieving carbon neutrality at the operational level for the third consecutive year, which demonstrates the Group’s unwavering commitment to climate action and sustainable development.In the second half of the year, guided by the “Steady Progress, Stability through Progress, Pragmatic Implementation” philosophy, the Group will optimise the revenue structure and drive the high-quality and sustainable development. The Group will adhere to a client-demand-driven approach, comprehensively strengthen integrated service capabilities across core businesses including wealth management, corporate finance, and global markets, build a full-cycle financial service system for institutional, corporate and individual clients, and provide more precise, diversified and efficient financial solutions for all classes of clients. Meanwhile, under its rigorous risk controls, the Group will proactively develop innovative business areas, deeply integrate the advantages of traditional finance and digital asset services, build a "one-stop digital financial service platform", and assist clients in seizing new opportunities for wealth growth in the Web3.0 era.For the full announcement, please visit：https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0827/2025082700592.pdfDisclaimer：This presentation does not constitute an offer or invitation to purchase or subscribe for any securities or financial instruments or the provision of any investment advice, and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto, nor does this presentation constitute a recommendation regarding the securities or financial instruments of the Company.This presentation contains certain forward-looking statements with respect to the financial conditions, results of the operations and business of the Company and certain plans and objectives of the management of the Company. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such forward-looking statements were based on assumptions regarding the Company’s present and future strategies and the political and economic environment in which the Company will operate in the future. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company’s management as of the date of this presentation only. There can be no assurance that future results or events will be consistent with any such forward-looking statements. About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - TechInnovation® 2025, Singapore’s preeminent platform for innovation and business transformation, returns for its 13th edition from 29–31 October 2025 at Sands Expo & Convention Centre, Level 3 Heliconia and Hibiscus Ballroom, Singapore. Organised by IPI Singapore, the three-day event will bring together over 40 expert speakers, more than 100 breakthrough technologies and curated programmes designed to accelerate real-world innovation and cross-border collaboration.Building on last year’s momentum, which brought together more than 100 exhibitors from 8 countries, attracted attendees from 42 markets, and resulted in over 30 projects supported by IPI Singapore after the event, TechInnovation 2025 will once again convene innovators, startups, corporates, and government agencies across Asia to showcase emerging technology solutions and forge strategic partnerships. In 2024, notably, 46 percent of visitors were senior management decision-makers, underscoring the event’s position as a high-value marketplace for business and technology leaders.The event focuses on sectors including smart buildings, urban solutions, engineering, digital health, sustainability, advanced manufacturing and AI, ensuring businesses can find solutions tailored to their growth ambitions while engaging directly with innovation leaders, potential collaborators and funding partners. Anchored on the theme Discover, Connect and Collaborate, TechInnovation 2025 offers exhibitors and visitors a platform to showcase ready-to-market technologies, connect with potential partners across borders, and co-create solutions to address real-world challenges faced by businesses.Innovation in Action: Interactive BoothsDebuting this year, TechInnovation 2025 will feature experiential technology showcases, giving select exhibitors the chance to showcase their ready-to-market technologies in a hands-on, interactive format. These interactive spaces are designed to spark conversations, encourage engagements and foster meaningful connections across the show floor. For SMEs, the booths offer a unique opportunity to showcase innovations, build credibility and connect directly with potential partners and customers. The launch responds to strong demand for immersive, real-world demonstrations that make technology tangible and memorable.Call for ExhibitorsTechInnovation 2025 invites technology providers, research institutions, startups and solution developers to participate as exhibitors. Exhibitors will benefit from exposure to thousands of decision-makers and industry leaders, targeted business matching opportunities and media visibility through IPI Singapore’s pre-event publicity and digital campaigns.“TechInnovation brings together enterprises and partners to explore new ideas,” said Michael Goh, Chief Operating Officer of IPI Singapore. “We look forward to welcoming exhibitors whose innovations can support practical business applications and contribute to a more sustainable and competitive future.”About TechInnovation 2025Returning for its 13th edition, TechInnovation 2025 is the flagship event of IPI Singapore, connecting technology seekers and providers across Asia. The event serves as a dynamic marketplace for co-innovation and tech adoption, drawing participation from startups, SMEs, corporates, universities and government agencies.This year’s theme, “Discover, Connect, Collaborate” underscores TechInnovation’s mission to drive growth through discovery, global connection and collaboration. The event will feature over 40 speakers, more than 100 technologies and 3 days of programming designed to scale real-world business innovation. TechInnovation is organised by IPI Singapore, a subsidiary of Enterprise Singapore and catalyst of Singapore’s open innovation ecosystem.TechInnovation® is a registered trademark of IPI Singapore.Learn more at www.techinnovation.com.sg.About IPI SingaporeIPI Singapore is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries. As a subsidiary of Enterprise Singapore, IPI Singapore accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.With a strong belief that innovation is key to enterprise growth, IPI Singapore provides enterprises with access to innovative ideas and technologies. IPI Singapore also facilitates and supports enterprises' innovation processes, including commercialisation and go-to-market strategies.Learn more at https://www.ipi-singapore.org/Media Contact:Sheree TanManager, Marketing & Communications, PartnershipsIPI Singapore ipi_comms@ipi-singapore.orgTheodore WoonDirectorPINPOINT PR Pte. Ltd.theodore@pinpointpr.global Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - On August 26, CaoCao Inc. (‘CaoCao’ or ‘Company’, Stock Code: 02643.HK) announced interim results. For the six months ended June 30, 2025, CaoCao Inc. operated in 163 cities. Company’s total order volume reached 379.5 million, representing an increase of 49.0% in the same period of last year. During the reporting period, the Company’s revenues increased by 53.5% to RMB 9.5 billion.The announcement shows that the Company’s gross profit margin raised from 7.0% in in the six months ended June 30, 2024 to 8.4% in the six months ended June 30, 2025., while losses narrowed by 39.8% year-on-year. Net cash generated from operating activities increased by 164.6% year-on-year, reflecting an improved financial position.CaoCao Inc. was founded in 2015, incubated by Geely Holding Group. According to Frost & Sullivan, CaoCao Inc. was the second largest ride hailing platform in China in terms of GTV in 2024.The Company has placed and expect to place greater strategic focus on purpose-built vehicles. As of June 30, 2025, it deployed a fleet of over 37 thousand purpose-built vehicles across 31 cities and and CaoCao also collaborated with local car partners through selling them our purpose-built vehicles. For the six months ended June 30, 2025, the GTV contributed by purpose-built vehicles amounted to RMB2.5 billion, reflecting an increase of 34.7% compared with the same period last year.The purpose-built vehicles specifically designed for shared mobility have significantly enhanced the driver and passenger experience. In the first half of the year, CaoCao Inc. saw a year-on-year increase of 57.4% in average monthly active users and 53.5% in average monthly active drivers, with the average order value (AOV) rising to RMB 28.9. In seven user surveys conducted between Q4 2023 and Q2 2025, CaoCao Mobility ranked in user recognition for “best service quality” among China’s leading shared mobility platforms.The company continues to invest in CaoCao Smart Mobility, their autonomous driving platform, to enhance our Robotaxi operation capabilities.Since April 2025, the company has been deploying their latest generation of Robotaxi, which features Geely’s latest redundant architecture design and deeply integrates CaoCao Smart Mobility’s capabilities in automated dispatching, remote safety assurance, travel cabin services, and asset digital management into a unified autonomous driving operation platform. The Company also collaborates with Geely and business partners to develop autonomous driving technology and to pre-install proprietary autonomous driving components and related applications in purpose-built vehicles. By the end of the reporting period, CaoCao Smart Mobility had accumulated over 15,000 kilometers of autonomous driving test mileage in Suzhou and Hangzhou. In addition, CaoCao Inc. continues to promote accessible mobility. On March 28, it officially launched their public welfare brand for accessibility, deploying over 1,000 accessible vehicles across 20+ major cities and holding a monthly “Accessibility Public Welfare Day” to provide free wheelchair-accessible travel for wheelchair users. At the same time, CaoCao Inc. is the first platform in the industry to participate in the pilot program for occupational injury protection for workers in new forms of employment, and has established support initiatives such as the Driver Care Fund and the Driver Children’s Education Fund.Looking ahead, CaoCao Inc. will leverage on competitive strengths, geographical expansion successes, tremendous momentum in Robotaxi development and strategic relationship with Geely Group, the company will continue to optimize their growth strategy, aiming to achieve a healthy combination of fast growth and profitability. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Queensland, AU, Aug 25, 2025 - (ACN Newswire via SeaPRwire.com) - Queensland’s rich First Nations culture, businesses, and industry leaders has been celebrated at World Expo 2025 in Osaka, Japan.The event was part of Queensland’s program as Gold Partner of the Australia Pavilion during Te Aratini Indigenous Peoples Week.Through business, art, food, and eco-tourism, artists, storytellers, performers, culinary innovators, and entrepreneurs from across Queensland’s diverse Aboriginal and Torres Strait Islander communities came together to showcase their talents and vision.Living Culture, Future Dreaming: From Queensland to the World explored deep connections between Country, culture, and community, highlighting exciting opportunities for collaboration between Queensland and Japan.Australian Ambassador for First Nations People, Justin Mohamed, attended the event, which featured a keynote address by Quandamooka artist and Trade and Investment Queensland (TIQ) Board Member Delvene Cockatoo-Collins. The program was emceed by Jamie Healey, TIQ’s First Nations Engagement Officer.Queensland’s Deputy Trade and Investment Commissioner for Japan, Melissa Inooka, led a compelling panel discussion spotlighting three pioneering First Nations entrepreneurs: Jacob Davidson, founder of FigJam & Co; Helen Bool, founder of Helen Rose Cosmetics and Wellness; and Kirra Daley, co-founder of Beachtree Distilling Co.Beachtree Distilling Co. was recently awarded World’s Best Craft Producer and World’s Best Sustainable Distillery at the 2025 World Drinks Awards in London.The panel explored the importance of engaging directly with First Nations communities and the surging global demand for bush food ingredients and native botanicals—showcasing the innovation and international impact of Indigenous-led enterprises.The event also highlighted cultural parallels between First Nations and Japanese traditions—shared values of provenance, ritual, craftsmanship, nature, and sustainability.Queensland student ambassadors Seth Johnson and Grace Winter shared their experiences representing the state in the Osaka World Expo Ambassador Program. Mr Johnson, from Bundaberg, carries Indigenous and South Sea Islander heritage and serves as House Captain and Indigenous leadership group member at Bundaberg State High School. Ms Winter, a proud Wiradjuri and Kamilaroi woman, is School and Indigenous Captain at Marsden State High School. Both spoke passionately about the power of education, culture, and youth leadership.Lagaw Titui representing Waiben (Thursday Island) presented a Dheori (headdress) to the officials of Wakayama Prefecture, their sister city, prior to the opening of the event.Throughout the week, Queensland’s First Nations pop-up at Lucua Osaka captivated the public as part of DEMOExpo—an initiative bringing the spirit of World Expo to the city streets.Performances by the Lagaw Titui Island Stars, a Meet the Maker pop up with Mrs Cockatoo-Collins, bespoke artworks and product displays by Hogarth Arts, Hopevale Arts, Yalanji Arts, MOA Arts, and Jedess Hudson brought Queensland’s First Nations stories to life for Japanese audiences.Mrs Cockatoo-Collins was captivated by the response and the genuine interest from local business networks.“The huge crowds at Lucua Osaka were incredible—it was a powerful reminder of how our stories and culture connect globally,” Cockatoo-Collins said.“Hosting Queensland’s First Nations event at World Expo 2025 Osaka has been an extraordinary opportunity to build meaningful connections and open doors for future collaboration in art, business, and community internationally.”Fast FactsJapan is Queensland’s third-largest goods export market with total exports valued at $14.2 billion as at June 2025.In 2024-25, Queensland’s goods exports totalled $104.8 billion, as the State continues to produce and supply globally competitive goods to meet external demands, despite a challenging global environment.Queensland remains Australia’s second-largest goods exporter after Western Australia, accounting for 20.4% of national goods exports, and exporting more than New South Wales and South Australia combined.Trade and Investment Queensland is the Queensland Government's dedicated global business agency with 27 locations across 18 international markets, helping Queensland companies access international markets and facilitate foreign investments in the state. For more information visit Trade and Investment Queensland.Media contact:Anita DuffinPrincipal Communications OfficerExpo 2025, Trade and Investment Queensland0484 369 222tiqmedia@tiq.qld.gov.au Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Key Results Highlights:- Revenue Growth: 5.8% increase to approximately HK$876.5 million.- Net Profit Increase: 3.8% rise to HK$163.4 million, driven by operational efficiency. - Interim Dividend: Proposed at HK$0.07 cents per share, 16.7% surge, up from HK0.06 in 2024.- Net Cash & Cash Equivalents: HK$ 640.5 million (HK$ 557.2 million in 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved for registration and commercialization in the PRC.- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA, marking a crucial regulatory milestone.Business Development:- Collaboration with Seefunge: For the Group to exclusively distribute Seefunge’s Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops.- Collabration with Airdoc: For parties to jointly operate Fundus AI business.Intellectual Property and Market Presence:- Robust IP Portfolio: 111 patent certificates or authorisation letters, comprising 81 invention patents, 15 utility model patents and 15 design patents.- Wide Distribution Network: Products available in over 14,100 hospitals and medical providers, and approximately 2,100 pharmaceutical stores across the PRCAwards and Recognition:- 2024 Top 100 Innovative Companies in Zhuhai: Recognised for innovation and quality- 2024 Top 100 Companies with Economic Contributions in Zhuhai: Acknowledged for significant economic impactHONG KONG, Aug 26, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced its interim results for the six months ended 30 June 2025 (“the period under review”).In the first half of 2025, the industry continued to face challenges from global geopolitical uncertainties and evolving domestic centralised procurement dynamics. However, supportive government policies fostering innovation and streamlined drug approval processes accelerated reimbursement cycles.Essex leveraged favorable trends and emerging opportunities, driving strong profitability growth and expand its market footprint. Our relentless focus on R&D innovation, strategic investments in flagship biologics, and expanded patient access in lower-tier cities in China contributed to resilient operational performance. The ongoing advancements in its healthtech e-platform also supported our growth momentum.Our achievements underscore Essex’s unwavering dedication to innovation and operational excellence, which drive sustained momentum in both revenue and profit growth.Strengthening Financial Position and Shareholder ReturnsDuring the period under review, the Group’s revenue was chiefly derived from its operations in the PRC and denominated in Renminbi. The Group achieved a consolidated turnover of approximately HK$876.5 million, with an increase of 5.8% as compared to approximately HK$828.5 million for the same period last year. The Group’s profit increased by 3.8% to approximately HK$163.4 million as compared to approximately HK$157.4 million for the same period last year.As of 30 June 2025, the Group had cash and cash equivalents of approximately HK$640.5 million (31 December 2024: approximately HK$557.2 million). The Group's gearing ratio remained stable at 29.7% (31 December 2024: 28.8%), reflecting the Group’s prudent financial management capabilities and strong liquidity.The Board is pleased to propose an interim dividend of HK$7.0 cents (for the six months ended 30 June 2024: HK$6.0 cents) per ordinary share for the six months ended 30 June 2025, underscoring the Group’s commitment to delivering shareholder value.Diversified Growth Fueled by Flagship BiologicsThe Group’s turnover is primarily made up of Ophthalmology and Surgical (encompassing wound care and healing) and provision of services segments. For the six months ended 30 June 2025, Ophthalmology contributed approximately HK$417.4 million to the Group’s turnover, while Surgical recorded a total turnover of approximately HK$449.0 million, representing about 47.6% and 51.2% of the Group’s total turnover, respectively. The core products that are current growth drivers under each segment are:1.Ophthalmology – Beifushu® series (Beifushu® eye drops, Beifushu® eye gel and Beifushu® unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Diquafosol Sodium Eye Drops, (Iodized Lecithin Capsules), Soft Hydrophilic Contact Lens and other medical devices for myopia control and prevention such as eye-protection lamp and Seewant defocus customised glasses;2.Surgical (encompassing wound care and healing) – Beifuji® series (Beifuji® spray, Beifuji® lyophilised powder and Beifuxin® gel), Carisolv® dental caries removal gel,(Dr. YaDian) oral care products, (Yi Xue An Granules), Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh® and Osteoplug®) for dental surgery in Singapore; and3.Provision of services – Healthtech e-platform related medical services.Currently, the Group has 6 self-developed and manufactured commercialised biologics (collectively referred to as the “bFGF Series”) that are marketed and sold in the PRC, and 3 of them were approved by NMPA as Category I biologics. The combined turnover of the bFGF Series represented about 83.5% of the Group’s total turnover for the period under review. Besides, the Group has a portfolio of commercialised preservative-free unit-dose eye drops and 2 oral care products, as well as a range of Ophthalmology and Surgical products and medical devices to complement the Group’s therapeutics business.Strategic R&D Secures Market-Leading MilestonesThe Group strategically invests in innovative products and technologies to enhance its R&D pipeline, dedicated to novel therapies that fulfill critical unmet medical and market demands. In the first half of 2025, total R&D expenditures were approximately HK$66.5 million, representing 7.6% of the turnover, of which approximately HK$44.8 million were capitalised.During the period, the Group obtained NMPA approval for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC. The approval is expected to enriching treatment options for chronic dry eye patients and further solidifying the Group’s leading position and overall competitiveness in the ophthalmology sector.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed the last visit for patient enrollment across multiple regions including the PRC, Australia, European Union countries and the United States. Notably, NMPA accepted the Biologics License Application (BLA) for this innovative therapy in August 2025, marking a crucial regulatory milestone.The Group holds a total of 111 patent certificates or authorisation letters, comprising 81 invention patents, 15 utility model patents and 15 design patents.The Group has multiple R&D sites located in Zhuhai (PRC), Boston (USA), London (UK) and Singapore, facilitating the development of innovative therapeutics and the attraction of international talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with 4 ophthalmology programs currently in late clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops, Azithromycin eye drops, and Cyclosporine eye drops, which are aimed at being mid-term growth drivers.Market Expansion and Operational EnhancementsAs at 30 June 2025, the Group maintains an extensive network of 46 regional sales offices in the PRC. With a vast distribution network, the Group’s products are prescribed in more than 14,100 hospitals and medical providers, as well as approximately 2,100 pharmaceutical stores, covering major cities throughout the PRC. The Group’s Singapore base has been gaining good development traction since 2020.In business development, the Group entered into a strategic cooperation with Airdoc to jointly operate fundus AI business. In addition, the Group has entered into an exclusive distribution agreement with Seefunge for the Seefunge’s Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops. Emedastine Fumarate Eye Drops is primarily used for treating allergic conjunctivitis in adults and children aged 3 years and above while Oxybuprocaine Hydrochloride Eye Drops is primarily used for corneal surface anesthesia. The new additions will further enrich the Group's ophthalmic product portfolio and strengthen its market positioning in ophthalmology.To sustain growth and expand its product portfolio, the Group has been actively enhancing competitiveness and market reach by broadening clinical indications of commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and advancing its healthtech e-platform to further improve patient accessibility.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, covering approximately 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026-2027.Mr. Patrick Ngiam, Chairman of Essex Bio-Technology, stated, “Our innovation-driven strategy, fueled by operational excellence, a strong financial foundation, and a growing market presence, positions us for sustainable growth and global expansion. We remain committed to improving patient outcomes and creating long-term value for shareholders.”About Essex (1061.HK)Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,100 hospitals, supported by the Company’s 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Website: http://www.essexbio.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com